{"id":23199,"date":"2023-01-29T04:58:00","date_gmt":"2023-01-28T20:58:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=23199"},"modified":"2023-01-29T05:59:24","modified_gmt":"2023-01-28T21:59:24","slug":"clin-infect-dis%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e6%b3%95%e5%8c%b9%e6%8b%89%e9%9f%a6%e6%b2%bb%e7%96%97%e6%97%a0%e7%97%87%e7%8a%b6%e6%88%96%e9%9d%9e%e5%a4%8d%e6%9d%82%e6%80%a7%e6%96%b0","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=23199","title":{"rendered":"[Clin Infect Dis\u53d1\u8868\u8bba\u6587]\uff1a\u6cd5\u5339\u62c9\u97e6\u6cbb\u7597\u65e0\u75c7\u72b6\u6216\u975e\u590d\u6742\u6027\u65b0\u51a0\u80ba\u708e\u95e8\u8bca\u60a3\u8005"},"content":{"rendered":"\n

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial <\/h1>\n\n\n\n

Marisa Holubar,\u00a0\u00a0Aruna Subramanian,\u00a0\u00a0Natasha Purington,\u00a0\u00a0et al<\/h3>\n\n\n\n

Clinical Infectious Diseases<\/em>, Volume 75, Issue 11, 1 December 2022, Pages 1883\u20131892,\u00a0https:\/\/doi.org\/10.1093\/cid\/ciac312<\/a><\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

Background<\/p>\n\n\n\n

Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro<\/em>activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite limited data, favipiravir is administered to patients with coronavirus disease 2019 (COVID-19) in several countries.<\/p>\n\n\n\n

Methods<\/p>\n\n\n\n

We conducted a phase 2, double-blind, randomized controlled outpatient trial of favipiravir in asymptomatic or mildly symptomatic adults with a positive SARS-CoV-2 reverse-transcription polymerase chain reaction assay (RT-PCR) within 72\u2005hours of enrollment. Participants were randomized to receive placebo or favipiravir (1800\u2005mg twice daily [BID] day 1, 800\u2005mg BID days 2\u201310). The primary outcome was SARS-CoV-2 shedding cessation in a modified intention-to-treat (mITT) cohort of participants with positive enrollment RT-PCRs. Using SARS-CoV-2 amplicon-based sequencing, we assessed favipiravir\u2019s impact on mutagenesis.<\/p>\n\n\n\n

Results<\/p>\n\n\n\n

We randomized 149 participants with 116 included in the mITT cohort. The participants\u2019 mean age was 43 years (standard deviation, 12.5 years) and 57 (49%) were women. We found no difference in time to shedding cessation overall (hazard ratio [HR], 0.76 favoring placebo [95% confidence interval {CI}, .48\u20131.20]) or in subgroups (age, sex, high-risk comorbidities, seropositivity, or symptom duration at enrollment). We detected no difference in time to symptom resolution (initial: HR, 0.84 [95% CI, .54\u20131.29]; sustained: HR, 0.87 [95% CI, .52\u20131.45]) and no difference in transition mutation accumulation in the viral genome during treatment.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions<\/p>\n\n\n\n

Our data do not support favipiravir at commonly used doses in outpatients with uncomplicated COVID-19. Further research is needed to ascertain if higher favipiravir doses are effective and safe for patients with COVID-19.<\/p>\n\n\n\n

Clinical Trials Registration<\/p>\n\n\n\n

NCT04346628.<\/p>\n","protected":false},"excerpt":{"rendered":"

Favipiravir for Treatment of Outpatients With Asymptoma […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23199"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23199"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23199\/revisions"}],"predecessor-version":[{"id":23434,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23199\/revisions\/23434"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}